2 citations
,
March 2019 in “Lasers in surgery and medicine” This study found that human hair follicles demonstrated a dose-dependent response to light in an ex vivo photoepilation model, which could predict the clinical efficacy and permanency of light-based hair removal devices.
September 2019 in “Journal of Investigative Dermatology” In this study, dose-response modeling predicted that once-daily abrocitinib doses of 100 mg and 200 mg may provide a clinically meaningful response in treating moderate-to-severe atopic dermatitis compared to placebo.
June 2022 in “Journal of Pakistan Association of Dermatologists” In this study, a 15-year-old male with alopecia areata universalis showed significant hair regrowth after an 8-month combination therapy, suggesting that comprehensive treatment, including antiviral, corticosteroid, and LED therapy, may be effective albeit long-term for managing this condition.
5 citations
,
February 2024 in “Clinical Pharmacokinetics” This study found that modeling and simulation effectively informed decision-making and dose selection for ritlecitinib in treating alopecia areata, supporting an accelerated drug development strategy.
In this study on C3H/HeJ-engrafted mice, a single injection of BMD-1141 significantly increased anagen hair follicle counts and enhanced hair regrowth compared to daily high-dose ruxolitinib, suggesting it stimulates hair growth by influencing the hair cycle rather than altering immune response.
